PF-06649751

DRUG5 trials

Sponsors

Pfizer

Conditions

HealthyIdiopathic Parkinson DiseaseParkinson DiseaseParkinson's Disease

Phase 1

A Phase I Trial to Investigate the Safety and Tolerability of PF-06649751

CompletedNCT01981694

Start: 2013-11-30End: 2014-02-28Updated: 2014-03-26

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of PF-06649751 in Parkinson's Disease

CompletedNCT02224664

PfizerParkinson's Disease

Start: 2014-10-31End: 2016-03-31Updated: 2017-03-27

A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of PF-06649751 Co-administered With Trimethobenzamide Hydrochloride in Healthy Subjects

CompletedNCT02262767

Start: 2014-11-30End: 2014-12-31Updated: 2015-01-14

A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of PF-06649751 in Subjects With Idiopathic Parkinson's Disease

CompletedNCT02373072

PfizerIdiopathic Parkinson Disease

Start: 2015-03-31End: 2016-03-31Updated: 2023-09-22

Phase 2

Efficacy, Safety and Tolerability of PF-06649751 in Parkinson's Disease Patients at Early Stage of the Disease

TerminatedNCT02847650

PfizerParkinson Disease

Start: 2016-10-17End: 2018-01-29Updated: 2020-11-23

Related Papers

PF-06649751 efficacy and safety in early Parkinson’s disease: a randomized, placebo-controlled trial

Therapeutic Advances in Neurological Disorders2020-01-0144 citations

Phase 1 Parkinson's Disease Studies Show the Dopamine D1/D5 Agonist PF-06649751 is Safe and Well Tolerated.

2018-10-2532 citations